MDT

97.79

-1.31%↓

149.06

+1.99%↑

VEEV

240.58

-0.77%↓

HQY

94.8

-2.61%↓

PHR.US

17.27

+1.95%↑

MDT

97.79

-1.31%↓

149.06

+1.99%↑

VEEV

240.58

-0.77%↓

HQY

94.8

-2.61%↓

PHR.US

17.27

+1.95%↑

MDT

97.79

-1.31%↓

149.06

+1.99%↑

VEEV

240.58

-0.77%↓

HQY

94.8

-2.61%↓

PHR.US

17.27

+1.95%↑

MDT

97.79

-1.31%↓

149.06

+1.99%↑

VEEV

240.58

-0.77%↓

HQY

94.8

-2.61%↓

PHR.US

17.27

+1.95%↑

MDT

97.79

-1.31%↓

149.06

+1.99%↑

VEEV

240.58

-0.77%↓

HQY

94.8

-2.61%↓

PHR.US

17.27

+1.95%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Open

1.96 -2

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.87

Max

2.03

Schlüsselkennzahlen
By Trading Economics
Angestellte	26

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.9M 14M
Vorheriger Eröffnungskurs	3.96
Vorheriger Schlusskurs	1.96

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Jan. 2026, 23:08 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8. Jan. 2026, 21:39 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8. Jan. 2026, 20:54 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks -- Update

8. Jan. 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Restart Merger Talks

8. Jan. 2026, 17:05 UTC

Akquisitionen, Fusionen, Übernahmen

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8. Jan. 2026, 16:43 UTC

Wichtige Markttreiber

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8. Jan. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. Jan. 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Jan. 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8. Jan. 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8. Jan. 2026, 21:53 UTC

Ergebnisse

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8. Jan. 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8. Jan. 2026, 21:09 UTC

Akquisitionen, Fusionen, Übernahmen

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8. Jan. 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8. Jan. 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8. Jan. 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8. Jan. 2026, 17:48 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Jan. 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Jan. 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8. Jan. 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8. Jan. 2026, 15:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Defends Its Hostile Bid for Warner -- Update

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.